Thermage Q2: Robust Results in Ailing Aesthetics Market
Despite the slowdown seen in the aesthetics market, second quarter revenue at Thermage totaled $17.9 million, a 2% increase over Q2 2007. International revenue increased […]
Healthcare Reform 2008: Evolution or Revolution?
Healthcare reform is high on the political agenda this year. The upcoming Presidential and Congressional elections promise to focus public and business leaders’ attention on […]
Signalife Throws in the Towel
After battling for over a year to retain its AMEX listing, Signalife has thrown in the towel. The company will voluntarily withdraw its common stock […]
HealthTronics Proposes Endocare Acquisition
HealthTronics has made an unsolicited bid to buy Endocare for $26.9 million in cash. The offer represents a 20% premium over Endocare’s closing stock price […]
[Video] Interview with Timothy Surgenor, President & CEO of Cyberkinetics Neurotechnology
Cyberkinetics Neurotechnology, at one time an oft-discussed early stage device firm, has seen a steady decline in share price. Current market conditions are largely to […]
Arbios Systems Runs Out of Steam
Arbios Systems has suspended operations and laid-off employees while it focuses on raising additional funds. If the company fails to secure financing by the end […]
Clarient Q2 Revenues Up 71%
Not wanting to break a winning streak, Clarient delivered its 16th consecutive quarter of quarterly revenue growth. The company posted revenues of $16.9 million in […]
NeuroMetrix: Revenues Decline, NC-Stat Prospects Bleak
NeuroMetrix reported quarterly revenues of $8.5 million yesterday, down approximately 26% from the same period in 2007. The company generated a scant $510,000 (or 6% […]
Chembio Q2 Results: Record Revenues, Net Loss Decreases
Chembio Diagnostics reported second quarter revenues of $2.72 million, an 8.6% increase over Q2 2007 and higher than any previous quarter. The lion’s share of […]
[Video] On Greatbatch, Stereotaxis: Interview with Keay Nakae, Analyst at Collins Stewart
In this video, Keay discusses Greatbatch, which he believes is a compelling buy based on its current valuation. Keay also discusses Stereotaxis. The company has […]